NCT06612047Recruiting
Comparison of 5.0T and 3.0T Biparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer
Comparison of 5.0T and 3.0T Biparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer: A Prospective, Single Center and Paired-design Diagnostic Study
Source: ClinicalTrials.gov · Last updated 11 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this observational study is to compare 5.0T and 3.0T biparametric magnetic resonance imaging in the diagnosis of prostate cancer. The main aims of this study are: * Compare the diagnostic efficacy of 5.0TbpMRI and 3.0TbpMRI for prostate cancer. Preliminarily evaluate the value of 5.0TbpMRI in diagnosing prostate cancer. * Compare and analyze the accuracy of 5.0TbpMRI and 3.0TbpMRI in determining the T stage of prostate cancer. Preliminary evaluation of the value of 5.0TbpMRI in determining the tumor stage of prostate cancer. The data of participants was collected prospectively.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 21 Sept 2024
- Start date
- 8 Oct 2024
- Primary completion date
- 30 Sept 2026
- Lead sponsor
- Anhui Provincial Hospital
- Diseases
- Prostate cancer
- NCT number
- NCT06612047
What you commit to
- Study type: Observational
- Planned participants: 150
- From 8 Oct 2024 to the primary completion date, 30 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- The patient has undergone other prostatic surgery in the past;
Other illness
- The patient has contraindications to MRI examination, such as metal plates and heart stents in the body;
Other
- The patient does not have an indication for prostate biopsy or refuses biopsy;
- The patient has contraindications to prostate biopsy;
- 3.0T MRI considers that the patient has multiple lymph node or bone metastases;
- The patient is unable to cooperate, has communication barriers, or refuses to sign the informed consent form.
Who the study is looking for
- The patient has at least one indication for prostate biopsy (Chinese expert consensus on prostate biopsy (2022 edition) );
- The primary prostate cancer has no other cancer history;
- The 3.0TbpMRI examination was completed, and the images were clear and accessible;
- The 5.0TbpMRI examination was further completed, and the images were clear and accessible;
- The patient fully understands the relevant content of the study and voluntarily signs the informed consent.
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Urology, The First Affiliated Hospital of USTC Coordinator of this site? Confirm its status | Hefei | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.